BioCentury
ARTICLE | Company News

Momenta, Virdante Pharmaceuticals deal

December 12, 2011 8:00 AM UTC

Momenta acquired Virdante's Sialic Switch assets, including IP and cell lines, relating to the sialylation of IV immunoglobulin ( IVIG) and other proteins for $4.5 million up front in cash. Virdante is eligible for an additional $51.5 million if certain development and regulatory milestones relating to three undisclosed products.

Momenta said the assets complement its technology platform, which performs detailed structural analysis of complex mixtures to develop generic versions of drugs and to discover and develop novel compounds. Sialic Switch uses enzymatic glycosylation to add a sialic acid to Fc-linked glycans of the pooled IgG antibodies of IVIG to treat autoimmune and inflammatory disorders. ...